Payment overview · 2025
General Payments
$273.81
8 reported records · 7 companies
Healthcare provider profile · identity verified
Jaffer Hussain, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · EDENTON, NC · NPI 1699218842
Verified facts
What the public records show
CMS Open Payments records show Jaffer Hussain, M.D. received $273.81 in general payments during 2025 across 8 reported records.
ABIOMED accounted for 54.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $149.93 | 54.8% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $32.38 | 11.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.87 | 11.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.18 | 6.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.00 | 5.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.76 | 5.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.69 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $273.81 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $32.38 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.87 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.87 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 936 | 235 |
| Amlodipine Besylate | Amlodipine Besylate | 612 | 153 |
| Losartan Potassium | Losartan Potassium | 589 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 525 | 120 |
| Omeprazole | Omeprazole | 445 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 391 | 103 |
| Gabapentin | Gabapentin | 363 | 94 |
| Lisinopril | Lisinopril | 363 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 309 | 87 |
| Furosemide | Furosemide | 299 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 80 |
| Metformin Hcl | Metformin Hcl | 276 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 267 | 72 |
| Ozempic | Semaglutide | 263 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 254 | 76 |
| Eliquis | Apixaban | 247 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 241 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 233 | 59 |
| Simvastatin | Simvastatin | 231 | 51 |
| Jardiance | Empagliflozin | 229 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 206 | 75 |
| Carvedilol | Carvedilol | 202 | 46 |
| Potassium Chloride | Potassium Chloride | 196 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 185 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 178 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 176 | 134 |
| Meloxicam | Meloxicam | 166 | 36 |
| Montelukast Sodium | Montelukast Sodium | 164 | 46 |
| Allopurinol | Allopurinol | 157 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 155 | 39 |
| Trazodone Hcl | Trazodone Hcl | 154 | 28 |
| Xarelto | Rivaroxaban | 151 | 24 |
| Metformin Hcl Er | Metformin Hcl | 143 | 39 |
| Sertraline Hcl | Sertraline Hcl | 130 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 28 |
| Spironolactone | Spironolactone | 119 | 33 |
| Valsartan | Valsartan | 117 | 33 |
| Famotidine | Famotidine | 115 | 36 |
| Prednisone | Prednisone | 113 | 80 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 113 | 65 |
| Januvia | Sitagliptin Phosphate | 108 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 57 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 105 | 26 |
| Alprazolam | Alprazolam | 103 | 25 |
| Tramadol Hcl | Tramadol Hcl | 103 | 28 |
| Ezetimibe | Ezetimibe | 98 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 98 | 19 |
| Ibuprofen | Ibuprofen | 94 | 38 |
| Synthroid | Levothyroxine Sodium | 91 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 88 | 19 |
| Atenolol | Atenolol | 84 | 23 |
| Bupropion Xl | Bupropion Hcl | 84 | 22 |
| Pregabalin | Pregabalin | 79 | 18 |
| Alendronate Sodium | Alendronate Sodium | 78 | 16 |
| Meclizine Hcl | Meclizine Hcl | 73 | 28 |
| Finasteride | Finasteride | 71 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 18 |
| Trulicity | Dulaglutide | 68 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 66 | 15 |
| Azithromycin | Azithromycin | 65 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 13 |
| Celecoxib | Celecoxib | 61 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 55 | 13 |
| Methylprednisolone | Methylprednisolone | 55 | 44 |
| Cephalexin | Cephalexin | 54 | 42 |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 13 |
| Benazepril Hcl | Benazepril Hcl | 50 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 15 |
| Repatha Sureclick | Evolocumab | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 11 |
| Lorazepam | Lorazepam | 47 | 14 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 15 |
| Fenofibrate | Fenofibrate | 44 | 11 |
| Donepezil Hcl | Donepezil Hcl | 41 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 12 |
| Ondansetron Odt | Ondansetron | 41 | 21 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Irbesartan | Irbesartan | 39 | 11 |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 21 |
| Klor-Con M20 | Potassium Chloride | 34 | 12 |
| Nitroglycerin | Nitroglycerin | 34 | 19 |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Bumetanide | Bumetanide | 31 | 11 |
| Valacyclovir | Valacyclovir Hcl | 31 | 16 |
| Baclofen | Baclofen | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Cefdinir | Cefdinir | 26 | 26 |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Klor-Con M10 | Potassium Chloride | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 18 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 21 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 19 |
| Ramipril | Ramipril | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Estradiol | Estradiol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Cartia Xt | Diltiazem Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | 12 |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Repatha Pushtronex | Evolocumab | 12 | suppressed |
| Singulair | Montelukast Sodium | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $273.81 · 8 records | ABIOMED | BREZTRI, Dexcom G6 Transmitter, NUZYRA, OTEZLA, REPATHA, Tyvaso, VOQUEZNA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error